Patents by Inventor Alan H. Calvert

Alan H. Calvert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8258175
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: September 4, 2012
    Assignee: Cancer Research Technology Limited
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Roger John Griffin, Bernard Thomas Golding, John Lunec, Martin E. M. Noble, David R. Newell, Alan H. Calvert
  • Publication number: 20080261917
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Application
    Filed: August 26, 2005
    Publication date: October 23, 2008
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Robert John Griffin, Bernard Thomas Golding, John Lunec, Martin E.M. Noble, David R. Newell, Alan H. Calvert
  • Patent number: 6677345
    Abstract: A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to differ from that of known CDK inhibitors such as olomoucine and roscovitine.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 13, 2004
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding, Jane A Endicott, Martin E M Noble, Francis T Boyle, Philip J Jewsbury
  • Patent number: 6310082
    Abstract: Benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R′ may each be selected independently from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: October 30, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding
  • Patent number: 6303618
    Abstract: Method of treating a tumour or other cell proliferation disorder which comprises administering an effective amount of a purine compound which inhibits cyclic dependent kinase activity. Novel purine compounds and pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: October 16, 2001
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding, Jane A Endicott, Martin E M Noble, Francis T Boyle, Philip J Jewsbury
  • Patent number: 6297250
    Abstract: A range of dipyridamole analogues useful for inhibiting transport of nucleosides or purines across cell membranes, thereby to potentiate the activity of various cytotoxic antitumor drugs, is disclosed.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: October 2, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger J Griffin, Nicola J Curtin, Bernard T Golding, Alan H. Calvert, David R. Newell
  • Patent number: 4564616
    Abstract: Quinazoline derivatives of formula: ##STR1## wherein R represents: (1) a straight or branched chain unsaturated hydrocarbon group, or(2) a straight or branched chain saturated or unsaturated hydrocarbon group which is substituted by at least one: heteroatom, the or each heteroatom being halogeno when R is a C.sub.1 hydrocarbon group; or saturated carbocyclic group; or group containing at least one heteroatom, the or each heteroatom being O, N or S when R contains a cyclic group; andn is O or an integer of 1-4;X or, when n is an integer of at least 2, each X independently, represents a halogeno, C.sub.1 -C.sub.4 alkyl, aryl or aralkyl group or a group including at least one heteroatom; andY represents a group of formula: ##STR2## wherein m.gtoreq.1 (poly-L-glutamates); and the pharmaceutically acceptable salts and esters thereof, which are suitable as anti-cancer agents.
    Type: Grant
    Filed: March 20, 1984
    Date of Patent: January 14, 1986
    Assignee: National Research Development Corporation
    Inventors: Terence R. Jones, Kenneth R. Harrap, Alan H. Calvert
  • Patent number: 4447608
    Abstract: Quinazoline derivatives of formula: ##STR1## wherein R represents: (1) a straight or branched chain unsaturated hydrocarbon group, or(2) a straight or branched chain saturated or unsaturated hydrocarbon group which is substituted by at least one: heteroatom, the or each heteroatom being halogeno when R is a C.sub.1 hydrocarbon group; or saturated carbocyclic group; or group containing at least one heteroatom, the or each heteroatom being O, N or S when R contains a cyclic group; andn is 0 or an integer of 1-4;X or, when n is an integer of at least 2, each Xindependently, represents a halogeno, C.sub.1 -C.sub.4 alkyl, aryl or aralkyl group or a group including at least one heteroatom; andY represents a group of formula: ##STR2## wherein m.gtoreq.1 (poly-L-glutamates); and the pharmaceutically acceptable salts and esters thereof, which are suitable as anti-cancer agents.
    Type: Grant
    Filed: October 19, 1982
    Date of Patent: May 8, 1984
    Assignee: National Research Development Corporation
    Inventors: Terence R. Jones, Kenneth R. Harrap, Alan H. Calvert